Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Price:
38.7 CNY
-0.9%
Market Closed
Updated:
May 13, 2024
Tibet Rhodiola Pharmaceutical Holding Co
Interest Income Expense
|
Tibet Rhodiola Pharmaceutical Holding Co
Interest Income Expense Peer Comparison
Comparables:
1099
S
601607
600998
C
600511
000963
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Interest Income Expense
-¥144.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-37%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Interest Income Expense
-¥3.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Interest Income Expense
-¥1B
|
CAGR 3-Years
-106%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Interest Income Expense
-¥1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-14%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Interest Income Expense
¥505.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
24%
|
CAGR 10-Years
22%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Interest Income Expense
-¥312.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-70%
|
CAGR 10-Years
-27%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Interest Income Expense?
Interest Income Expense
-144.7m
CNY
-144.7m
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Interest Income Expense amounts to -144.7m CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-37%
-37%
Over the last year, the Interest Income Expense growth was -1 214%.
You don't have any saved screeners yet
